Approaches in the Management of Renal Cell
Carcinoma (RCC): A Closer Look at Advances in Immunotherapy
in an Evolving Treatment Paradigm
medical education activity sponsored by NAMCP and AAMCN
Novel Treatment Approaches in the Management of Renal Cell
Carcinoma (RCC): A Closer Look at
Advances in Immunotherapy in an
Evolving Treatment Paradigm is a 3-part webcast series that will
explore the latest clinical advances and recent data the
treatment and management of RCC.
By clicking on
each of the titles, you will be able to participate in each part.
It is not required that you participate in all 3 or in order.
These are archives of live webinars held between July 26, 2019 and August 9,
If you participated in any of the live webinars, you are not eligible to claim
credit from the archive of that webinar.
Each session has
its own specific valid dates
This series is supported by an educational grant
Sharp & Dohme Corp.
This activity is intended for healthcare professionals practicing in managed
CME/CNE: Complete the pre-test, listen to the audio and view the slides,
complete the post test, complete the evaluation form and hit submit. You will be
asked to enter your name and email address on the pre-test, evaluation and
post-test. If you close your internet browser without completing the post test,
you will have ONE more opportunity to complete. A score of 70% must be achieved
on the post test to receive continuing education credits. If you do not pass the
post test after two attempts, you will not be eligible to try again. Once you
complete the evaluation form and score 70% or higher on your post test, you will
automatically be given your certificate.
Managed Care and clinical decision-making in the setting of advanced renal cell
carcinoma (RCC) has been undergoing dramatic change in the past few years. The
approval of new immunotherapeutic agents has expanded the lines of therapy
available to patients, especially around combination options, and raised
questions about how rational treatment planning and effective sequencing of new
and older standards of care can optimize patient outcomes. Additionally, the
benefit of real-world experience and data from subgroup analyses and long-term
follow-up of landmark clinical trials continue to refine treatment strategies in